LPL Financial LLC Grows Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

LPL Financial LLC raised its position in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 83.8% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 676,212 shares of the company's stock after buying an additional 308,334 shares during the period. LPL Financial LLC owned 0.17% of Moderna worth $19,171,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of the business. Empirical Finance LLC increased its position in shares of Moderna by 7.3% during the 1st quarter. Empirical Finance LLC now owns 9,215 shares of the company's stock valued at $261,000 after purchasing an additional 624 shares during the last quarter. HB Wealth Management LLC purchased a new position in Moderna in the first quarter valued at about $225,000. Cetera Investment Advisers grew its position in shares of Moderna by 20.7% during the 1st quarter. Cetera Investment Advisers now owns 49,215 shares of the company's stock valued at $1,395,000 after acquiring an additional 8,432 shares during the period. John G Ullman & Associates Inc. increased its stake in shares of Moderna by 45.1% during the 1st quarter. John G Ullman & Associates Inc. now owns 14,950 shares of the company's stock worth $424,000 after purchasing an additional 4,650 shares during the last quarter. Finally, Old Port Advisors lifted its stake in Moderna by 23.5% in the first quarter. Old Port Advisors now owns 15,534 shares of the company's stock valued at $440,000 after purchasing an additional 2,958 shares during the last quarter. 75.33% of the stock is currently owned by institutional investors.

Moderna Price Performance

Shares of MRNA traded down $0.76 on Wednesday, reaching $26.71. The company's stock had a trading volume of 10,141,515 shares, compared to its average volume of 10,907,343. The stock's 50 day simple moving average is $29.27 and its two-hundred day simple moving average is $30.17. The stock has a market capitalization of $10.39 billion, a P/E ratio of -3.55 and a beta of 1.83. Moderna, Inc. has a 12-month low of $23.15 and a 12-month high of $91.99.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its quarterly earnings data on Friday, August 1st. The company reported ($2.13) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.99) by $0.86. Moderna had a negative net margin of 94.31% and a negative return on equity of 25.96%. The firm had revenue of $142.00 million during the quarter, compared to the consensus estimate of $116.26 million. During the same quarter in the previous year, the firm posted ($3.33) EPS. The company's revenue for the quarter was down 41.1% compared to the same quarter last year. Analysts expect that Moderna, Inc. will post -9.61 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. Barclays lowered their target price on Moderna from $40.00 to $31.00 and set an "equal weight" rating on the stock in a research note on Monday. UBS Group cut their target price on shares of Moderna from $78.00 to $70.00 and set a "buy" rating for the company in a research report on Friday, May 2nd. Wells Fargo & Company reissued an "equal weight" rating on shares of Moderna in a report on Sunday, July 13th. Evercore ISI set a $32.00 price objective on Moderna in a research note on Friday, August 1st. Finally, JPMorgan Chase & Co. set a $26.00 target price on Moderna in a report on Friday, August 1st. Four equities research analysts have rated the stock with a sell rating, seventeen have given a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Moderna currently has a consensus rating of "Hold" and an average price target of $45.61.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.